LATECOERE (LAT.PA)

FR001400JY13 - Common Stock

0.0101  +0 (+3.06%)

Fundamental Rating

2

Overall LAT gets a fundamental rating of 2 out of 10. We evaluated LAT against 36 industry peers in the Aerospace & Defense industry. LAT has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, LAT is valued expensive at the moment.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LAT has reported negative net income.
In the past year LAT has reported a negative cash flow from operations.
LAT had negative earnings in 4 of the past 5 years.
In the past 5 years LAT reported 4 times negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -17.69%, LAT is doing worse than 91.18% of the companies in the same industry.
Industry RankSector Rank
ROA -17.69%
ROE N/A
ROIC N/A
ROA(3y)-23.52%
ROA(5y)-14.95%
ROE(3y)-396.82%
ROE(5y)-240.93%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

LAT has a Gross Margin (36.63%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of LAT has remained more or less at the same level.
LAT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 36.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.07%
GM growth 5Y-0.89%

More info and screens

0

2. Health

2.1 Basic Checks

LAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LAT has more shares outstanding
The number of shares outstanding for LAT has been increased compared to 5 years ago.
The debt/assets ratio for LAT is higher compared to a year ago.

2.2 Solvency

LAT has an Altman-Z score of -0.39. This is a bad value and indicates that LAT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of LAT (-0.39) is worse than 88.24% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.39
ROIC/WACCN/A
WACC4.66%

2.3 Liquidity

LAT has a Current Ratio of 0.99. This is a bad value and indicates that LAT is not financially healthy enough and could expect problems in meeting its short term obligations.
LAT has a Current ratio of 0.99. This is in the lower half of the industry: LAT underperforms 73.53% of its industry peers.
A Quick Ratio of 0.47 indicates that LAT may have some problems paying its short term obligations.
LAT has a Quick ratio of 0.47. This is in the lower half of the industry: LAT underperforms 79.41% of its industry peers.
Industry RankSector Rank
Current Ratio 0.99
Quick Ratio 0.47

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 39.96% over the past year.
LAT shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.00%.
Measured over the past years, LAT shows a decrease in Revenue. The Revenue has been decreasing by -6.56% on average per year.
EPS 1Y (TTM)39.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.95%
Revenue 1Y (TTM)41%
Revenue growth 3Y-13.08%
Revenue growth 5Y-6.56%
Sales Q2Q%43.01%

3.2 Future

LAT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.99% yearly.
LAT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.87% yearly.
EPS Next Y38.99%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue Next Year29.67%
Revenue Next 2Y22.51%
Revenue Next 3Y17.87%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

LAT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, LAT is valued more expensive than 82.35% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 45.21

4.3 Compensation for Growth

A more expensive valuation may be justified as LAT's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LAT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LATECOERE

EPA:LAT (12/30/2024, 7:00:00 PM)

0.0101

+0 (+3.06%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryAerospace & Defense
Earnings (Last)09-24 2024-09-24
Earnings (Next)N/A N/A
Inst Owners0.47%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap126.22M
Analysts42.86
Price Target0.01 (-0.99%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.27
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 45.21
EPS(TTM)-0.07
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0.04
BVpS0
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.69%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 36.63%
FCFM N/A
ROA(3y)-23.52%
ROA(5y)-14.95%
ROE(3y)-396.82%
ROE(5y)-240.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.07%
GM growth 5Y-0.89%
F-Score5
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 25.95
Cap/Depr 101.46%
Cap/Sales 11.72%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.99
Quick Ratio 0.47
Altman-Z -0.39
F-Score5
WACC4.66%
ROIC/WACCN/A
Cap/Depr(3y)52.2%
Cap/Depr(5y)79.94%
Cap/Sales(3y)5.75%
Cap/Sales(5y)6.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.95%
EPS Next Y38.99%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue 1Y (TTM)41%
Revenue growth 3Y-13.08%
Revenue growth 5Y-6.56%
Sales Q2Q%43.01%
Revenue Next Year29.67%
Revenue Next 2Y22.51%
Revenue Next 3Y17.87%
Revenue Next 5YN/A
EBIT growth 1Y33.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.23%
EBIT Next 3Y29.29%
EBIT Next 5YN/A
FCF growth 1Y-152.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-101.42%
OCF growth 3YN/A
OCF growth 5YN/A